關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Banking/Financial Service」新聞搜尋結果, 共 10086 篇 ,以下為 169 - 192 篇 訂閱此列表,掌握最新動態
Year-opening Triumph: Arctech Lands a 1.5GW Solar Project Order in the UAE

ABU DHABI, UAE, Jan. 3, 2025 /PRNewswire/ -- Arctech, the world's leading solar tracking and racking solutions provider, announced that it signed a 1.5GW order of its 1P single-axis solar tracking system SkyLine II with PowerChina for a solar project in Al Ajban, UAE, marking a great start for the company in the Middle East market in 2025. As a key initiative under "UAE Energy Strategy 2050", which aims to provide the country with zero-emission clean energy, this 1.5GW Al Ajban Solar PV plant will become one of the largest single-site solar plants worldwide once completed. Groundbreaking Ceremony of 1.5GW Al Ajban Solar PV plant Upon completion, this plant is projected to generate green electricity capable of fulfilling the electricity demands of approximately 160,000 households. It is expected to reduce Abu Dhabi's annual carbon emissions by 2.4 million tons each year, thereby significantly advancing green development and facilitating energy transition in the Middle East. Since establishing its local operations in 2017, Arctech has expanded to include a service center, an R&D center, two local offices and a manufacturing base in the Middle East. Among which, Arctech's Jeddah Phase II manufacturing base is currently under construction and will officially enter operation in 2025. Combined with its global supply chain, this expansion will enable Arctech to achieve a local delivery capacity of 15GW. Up to now, Arctech has established a complete full life cycle service network in the Middle East market, including technical support, supply chain delivery, after-sales service, local operation and maintenance capabilities, and brand marketing strategies. Looking ahead, Arctech is well-positioned to further contribute to UAE's "Energy Strategy 2050" through its enhanced localization initiatives and comprehensive white-glove services. About Arctech Arctech (SSE-STAR:688408) is the world-leading supplier of intelligent solar trackers, fixed-tilt structures, PV cleaning robots and energy storage solutions. Empowered by over 530 patents, Arctech products have been applied in utility-scale and commercial solar PV projects since 2009. It was listed among the top 4 tracker suppliers by IHS Markit and Wood Mackenzie from 2017 to 2020. The company went public on China's Nasdaq-style STAR market in 2020. As of June 2024, Arctech has supplied over 76 GW of tracking and racking systems to nearly 1,800 PV plants in 40 countries. For more information, please visit https://www.arctechsolar.us/. Follow us on Linkedin, Twitter, Facebook and YouTube.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 196 加入收藏 :
OneConstruction Group Limited Announces Closing of Initial Public Offering

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- OneConstruction Group Limited ("OneConstruction Group" or the "Company"), a structural steelwork contractor in Hong Kong, today announced the closing of its initial public offering of 1,750,000 ordinary shares at a public offering price of US$4.00 per share (the "Offering"). The Company has granted the underwriters a 45-day option to purchase up to 262,500 additional ordinary shares, representing 15% of the aggregate number of ordinary shares sold in the Offering at the initial public offering price, less underwriting discounts. The Company's ordinary shares began trading on the Nasdaq Capital Market on December 31, 2024, under the ticker symbol "ONEG", subject to customary closing conditions. The aggregate gross proceeds from the Offering were $7 million, before deducting underwriting discounts and other related expenses. The Company intends to use the net proceeds from the Offering to fund up-front costs for future projects, expand management and technical teams, and bolster working capital. The Offering was conducted on a firm commitment basis. American Trust Investment Services and WestPark Capital acted as Underwriters. WestPark Capital was the book-running manager for the Offering. Hunter Taubman Fischer & Li LLC acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities counsel to the underwriters in connection with the Offering. A registration statement on Form F-1 (File No. 333-28316) relating to the Offering, as amended, has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on December 20, 2024. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus related to the Offering may be obtained, when available, from WestPark Capital, Inc. or American Trust Investment Services, Inc., by email at syndicate@wpcapital.com or ECM@amtruinvest.com, respectively, by standard mail to WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA, 90067 or American Trust Investment Services, Inc., 230 W. Monroe Street, Suite 300, Chicago, IL 60606, respectively, or by telephone at (310) 843-9300 or 312-382-7000, respectively. In addition, a copy of the final prospectus, when available, can also be obtained via the SEC's website at www.sec.gov. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About OneConstruction Group OneConstruction Group is a structural steelwork contractor in Hong Kong. The Company, through its subsidiaries, specializes in the procurement and installation of structural steel for a diverse range of construction projects in Hong Kong (including residential and commercial development as well as infrastructure projects), serving both public and private sector clients. For more information, please visit the Company's website: www.OneConstruction.com.hk Forward-Looking Statements All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this prospectus. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement, each of which is expressly qualified by the statements in this section, to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. Contacts Media RelationsMs. Callis Lau / Mr. Gary Li / Ms. Lorraine Luk/ Mr. Himo Liuoneg@iprogilvy.com Investor RelationsMr. Gordon Ligli@oneconstruction.com.hk

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 323 加入收藏 :
Cathay United Bank Launches First "Taiwan Premium Health Check-Up & Accommodation" Package for Affluent Cambodian Customers

TAIPEI, Jan. 3, 2025 /PRNewswire/ -- With over a decade of experience in developing the Cambodian market, Cathay United Bank has recently expanded its corporate and consumer banking services in Cambodia, aligning with the Cathay Financial Holdings' strategic development goals. To enhance services for its affluent credit and debit cardholders, Cathay United Bank Cambodia (CUBC) has partnered with Visa, a leading payment technology company, in a first-ever collaboration. This collaboration features the Cathay Healthcare Management Dun-Nan Center and the Madison Taipei Hotel—a boutique hotel under Cathay Hospitality Management—offering Cambodian cardholders access to professional medical services in Taiwan, along with a luxurious and relaxing experience through its premium health check package. This package is available from now until December 15, 2025. CUBC President Kevin Yeh emphasized that Cathay United Bank has over a decade of experience in Cambodia's credit card industry and was the first bank in the country to issue the Visa Infinite Card. From 2023 to the present, the top 2% of cardholders have contributed an impressive 45% of CUBC's total card transaction volume. The demand for premium medical services among high-end Cambodian customers has grown significantly in recent years, with many opting to travel overseas for medical treatments and health checks each year. Popular destinations include Thailand, Singapore, and Taiwan. According to the 2024 edition of the CEOWORLD Magazine Health Care Index, Taiwan has been ranked as the country with the world's best healthcare system. To cater to its high-end customers, CUBC has leveraged the Cathay Group's healthcare and hospitality resources to offer a luxurious healthcare holiday. In addition to premium health checks, customers will enjoy dedicated services such as a personal butler at Madison Taipei Hotel, chauffeur service, etc., offering them an opportunity to experience the timeless charm of Taiwan. CUBC Visa Infinite cardholders who book the premium health check package are eligible for a 3% rebate on transactions made at department stores or restaurants in Taiwan until May 31, 2025. Furthermore, they can redeem 100% of their CashPoint for health checks and accommodation expenses until December 31, 2025. With CUBC's Visa Infinite card, customers can enjoy exclusive, upscale services in style. Table: CUBC Premium Health Check in Taiwan Package (12/16/2024-12/15/2025). Please refer to the official website:  www.cathaybk.com.kh/personal/card-promotions Health Check A comprehensive checkup at Dun-Nan Healthcare Center Limited to 2 individuals per day. The health check includes MRI of seven regions, 640-slice CT Cardiac CTA, brain and carotid MRA, low-dose lung CT, cardiovascular examinations, DXA whole-body fat analysis, optical coherence tomography, etc.   Accommodation Madison Taipei HotelRenowned for its subtle luxury and understated elegance, Madison Taipei Hotel is a boutique hotel under Cathay Hospitality Management. The hotel has been recommended by the Michelin Guide Taipei, earned distinctions at the World Luxury Hotel Awards for three consecutive years, and was ranked among the top 25 of Tripadvisor Travellers' Choice Awards. Madison Taipei Hotel offers customers the dedicated services of British-style butler service. In addition to exclusive accommodation offers, this delightful package also includes a chauffeur to drive customers to their premium health check.   CUBC Visa Infinite Card   Until May 31, 2025:Customers can enjoy a 3% rebate on transactions made at department stores and restaurants in Taiwan Until December 31, 2025:100% of CashPoint can be redeemed for health check and accommodation expenses.     CUBC has teamed up with Visa, a leading payment technology company, along with Cathay Healthcare Management Dun-Nan center and Madison Taipei Hotel, to provide affluent cardholders in Cambodia an opportunity to receive professional medical services.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 431 加入收藏 :
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The approval is based on positive results from the pivotal Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated the safety, tolerability and efficiency of taletrectinib in Chinese patients with advanced ROS1-positive NSCLC. The findings, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology (JCO), demonstrated that taletrectinib continued to show high and durable overall responses and robust activity against intracranial lesions. In ROS1 TKI-naïve (n=106) patients, confirmed objective response rate (cORR, as assessed by an independent review committee, IRC) and intracranial cORR reached as high as 91% and 88%, respectively. After median follow-up of 23.5 months in TKI-naïve patients, median duration of response (IRC-assessed) and median progression-free survival (IRC-assessed) were not reached. [Link] In December 2024, DOVBLERON® was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. DOVBLERON® is the 13th addition to Innovent's commercial portfolio, representing an innovative precision therapy expected to benefit more lung cancer patients alongside our strong TKI franchise. Caicun Zhou, M.D., Ph.D., Director of the Department of Oncology at Shanghai East Hospital, Tongji University, commented: "We are glad to see that DOVBLERON® has been approved for ROS1-positive NSCLC across treatment lines at a fast pace. DOVBLERON® demonstrated superior efficacy compared to the first-generation TKIs. These TRUST-I results reinforce taletrectinib's high overall response and prolonged PFS. The efficacy and safety profile of DOVBLERON® offers a more effective first-line treatment option and I look forward to its benefit in the ROS1-positive NSCLC patients in China." Dr. Hui Zhou, Senior Vice President of Innovent, stated: "The two NDAs approval of DOVBLERON® is a reflection of its potential best-in-class efficacy to fulfill the urgent need of patients with ROS1-positive NSCLC. We recently just launched the first batch of DOVBLERON® to market, rapidly bringing this precision therapy to NSCLC patients who need novel treatment options. Innovent's robust TKI product pipeline—including RETSEMOV®, PEMAZYRE®, DUPERT® and DOVBLERON®—showcases our leadership and synergistic strengths in precision oncology. We endeavor to advance more innovative medicines to enhance patients' quality of life." About ROS1-positive Non-small Cell Lung Cancer Lung cancer continues to have one of the highest global incidences and mortality rates, with NSCLC accounting for about 85% of all cases. In China, it is estimated that approximately 2.6% of patients living with NSCLC are ROS1-positive[i]. Despite recent progress for patients with ROS1-positive NSCLC, there remains a need for more effective and tolerable treatment options. In patients with metastatic ROS1-positive NSCLC that progressed following initial treatment, many have tumors spread to their brain (up to 55%) or acquired resistance mutations, including G2032R. Next-generation ROS1 TKIs demonstrated robust intracranial and G2032R activity. In the clinical management of ROS1-positive NSCLC patients, the first-line application of the new generation ROS1 TKIs can bring a prolonged progression-free survival and provide patients with greater survival benefits. About DOVBLERON ® (Taletrectinib Adipate Capsule) DOVBLERON® is an oral, potent, central nervous system-active, selective, next-generation ROS1inhibitor. Taletrectinib, the active ingredient in DOVBLERON® is being evaluated for the treatment of patients with advanced ROS1-positive NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study. DOVBLERON® was approved by China's National Medical Products Administration (NMPA): 1) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who have previously been treated with ROS1 TKIs; 2) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. Taletrectinib has been granted Orphan Drug Designation by the U.S. FDA for the treatment of patients with ROS1-positive NSCLC and other NSCLC indications, and Breakthrough Therapy Designations by both the U.S. FDA and China's NMPA for the treatment of patients with locally advanced or metastatic ROS1-positive NSCLC. Based on pooled results of the TRUST-I and TRUST-II clinical studies, Nuvation Bio Inc. (NYSE: NUVB) submitted an NDA for taletrectinib to the U.S. FDA for the treatment of patients with advanced ROS1-positive NSCLC (line agnostic, full approval). This NDA was accepted by the U.S. FDA for priority review in December 2024. In June 2021, Innovent and AnHeart Therapeutics (Hangzhou) Co. Ltd., a Nuvation Bio Inc. company, entered into an exclusive license agreement for the co-development and commercialization of taletrectinib in Greater China, including mainland China, Hong Kong, Macau and Taiwan. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. References [i] Zhang et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer. 2019 Jan;10(1):47-53.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 528 加入收藏 :
DataLend: 2024 Securities Lending Revenue Down 10% YoY to $9.64 Billion

Lending revenue dips against backdrop of record-high indices NEW YORK, Jan. 3, 2025 /PRNewswire/ -- The global securities finance industry generated $9.64 billion in revenue for lenders in 2024, according to DataLend, the market data service of fintech EquiLend. The figure represents a 10.3% decrease from the $10.74 billion generated in 2023. Global broker-to-broker activity, where broker-dealers lend and borrow securities from each other, totaled an additional $2.57 billion in revenue for 2024, a 9.9% decrease from 2023. Equity lending revenues fell 13% globally, with North America revenue declining 15% and EMEA revenue dropping 24%. In North America, the cause for the revenue decline was a 19% decrease in average fees, while in EMEA, fees and balances decreased 16% and 11%, respectively. Equity lending revenues in APAC were largely flat year-over-year. Global sovereign debt revenue increased by 8% over 2023, with U.S. treasuries making up the lion's share of the gains. Treasuries were up 16% year-over-year, driven by a 14% growth in balances. In corporate debt lending, global revenue declined by 21% as a regression from a record 2023 continued. Fees were the main culprit, with a steep 29% decrease driving the year-over-year decline in revenue. The top five earning securities in 2024 were Sirius XM Holdings (SIRI US), Lucid Group (LCID US), Beyond Meat Inc. (BYND US), Tempus AI Inc. (TEM US) and Trump Media & Technology Group (DJT US). The five securities in total generated $644 million for lenders over the course of 2024, a significant dip from the $1.11 billion generated by 2023's top five earners. Bloomberg Terminal users can subscribe to EquiLend's exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA <GO> or clicking the following link: https://blinks.bloomberg.com/screens/apps%20orbisa. About DataLendDataLend, the market data service within EquiLend's Data & Analytics Solutions group, tracks daily market movements across more than 200,000 securities, covering $35 trillion in lendable assets and $2.6 trillion in on-loan assets for the securities finance market. www.datalend.com  About EquiLendEquiLend is a global financial technology firm offering Trading, Post-Trade, Data & Analytics, RegTech and Platform Solutions for the securities finance industry. EquiLend has offices in North America, EMEA and Asia-Pacific and is regulated in jurisdictions around the globe. www.equilend.com  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 457 加入收藏 :
CUBE COMPLETES ACQUISITION OF THOMSON REUTERS REGULATORY INTELLIGENCE AND ODEN BUSINESSES

Acquisition delivers an expanded customer base with a deep global subject matter expertise network that further powers CUBE's RegBrain AI across its industry proven SaaS RegPlatform™ CUBE continues to see strong organic customer growth in its well-established enterprise sector whilst also accelerating growth across the mid-market sector  2024 was a year of strategic milestones for CUBE including the partnership with Hg, expanding its global footprint across six main hubs, the acquisition of Reg-Room and Thomson Reuters Regulatory Intelligence and Oden businesses, together with pivotal board and executive appointments LONDON, Jan. 3, 2025 /PRNewswire/ -- CUBE, a global leader in Automated Regulatory Intelligence (ARI) and Regulatory Change Management (RCM), has today formally announced the completion of its acquisition of the Thomson Reuters Regulatory Intelligence and Oden businesses on 31 December 2024. The acquisition of these global businesses is another step forward in CUBE's growth plans as a leader in regulatory intelligence. It will supplement and enhance CUBE's ability to deliver significant scale across many of the world's leading and systemically important financial institutions. CUBE's global customer base will expand to total approximately 1,000 customers in banking, insurance, asset and investment management, payments and adjacent regulated industries. CUBE's Founder and CEO, Ben Richmond, said: "The completion of this acquisition is a major milestone for CUBE in a year that has seen many important milestones including our strategic partnership with Hg, the acquisition of Reg-Room, and the acquisition of Thomson Reuters Regulatory Intelligence and Oden businesses." "Thomson Reuters is best known in the industry for providing regulatory analysis and subject matter expertise combined with world-leading journalism and news," said Ben Richmond. "The powerful combination of CUBE's AI and the years of human generated content curated by Thomson Reuters Regulatory Intelligence and Oden subject matter experts sets us apart in the industry. This new dimension at CUBE will accelerate innovation and drive further growth and opportunity in 2025 and beyond." Following the announcement of its strategic partnership with Hg in March 2024, CUBE has now completed two transformational US-based acquisitions across three businesses whilst continuing to assemble a highly experienced executive team. CUBE's continued impressive growth saw its presence in the enterprise sector surpassing 200 customers and now represents around 40% of Tier 1 financial institutions globally. In the mid-market sector, serving small and medium sized enterprises, CUBE now has near 800 customers. With this growth CUBE solidified its global footprint by establishing offices across its six main hubs focused on customer support and implementation; with the number of employees at CUBE doubling to near 700 and a comparable increase in the number of countries where CUBE's employees are located, which now totals 15 countries. Ben Richmond said: "We are excited to welcome all of our new colleagues to CUBE – 2025 promises to be yet another significant year for the business as we continue to deliver further innovation focused on automating regulatory compliance and risk management for our customers." The definitive agreement was originally announced in May 2024 and terms were not disclosed.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 415 加入收藏 :
2025 年 1 月 21 日 (星期二) 農曆十二月廿二日
首 頁 我的收藏 搜 尋 新聞發佈